- Conditions
- Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
- Interventions
- ALE.P03
- Drug
- Lead sponsor
- Alentis Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 368
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- RXDX-106
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Lung Cancer
- Interventions
- immunohistochemistry staining method, biopsy, surgery
- Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 56
- States / cities
- Mobile, Alabama • Los Angeles, California • Pasadena, California + 37 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2013
- U.S. locations
- 15
- States / cities
- Urbana, Illinois • Indianapolis, Indiana • Cedar Rapids, Iowa + 10 more
- Conditions
- Anxiety Disorder, Depression, Fatigue, Lung Cancer
- Interventions
- cisplatin, fluoxetine, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 42
- States / cities
- Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more
- Conditions
- Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer, Bronchioloalveolar Lung Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Cixutumumab, Paclitaxel
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 165
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 122 more
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, docetaxel, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Nathan Pennell, MD, PhD
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Cleveland, Ohio • Mayfield Heights, Ohio
- Conditions
- Lung Cancer
- Interventions
- carboplatin, cisplatin, efaproxiral, gemcitabine hydrochloride, paclitaxel, vinorelbine ditartrate, radiation therapy
- Drug · Procedure
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Coeur d'Alene, Idaho • Lexington, Kentucky + 4 more
- Conditions
- Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer
- Interventions
- PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 226
- States / cities
- Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 164 more
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor
- Interventions
- WTX-124, pembrolizumab
- Drug
- Lead sponsor
- Werewolf Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more
- Conditions
- Solid Tumor, Adult
- Interventions
- DF9001, KEYTRUDA® (pembrolizumab)
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis
- Drug · Genetic · Other
- Lead sponsor
- Greg Otterson
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Neoplasms
- Interventions
- GSK3052230, paclitaxel, carboplatin, docetaxel, pemetrexed, cisplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 10
- States / cities
- Duarte, California • Sacramento, California • Chicago, Illinois + 7 more
- Conditions
- Lung Cancer
- Interventions
- stereotactic body radiation therapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 2
- States / cities
- Rochester, New York • Houston, Texas
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Rucaparib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 950
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
- Interventions
- PF-07209960
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Interventions
- TAK-186
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
- Interventions
- silevertinib (BDTX-1535) monotherapy
- Drug
- Lead sponsor
- Black Diamond Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
- Interventions
- vobramitamab duocarmazine
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- ASP388B, Pembrolizumab, Carboplatin, Oxaliplatin, 5-fluorouracil
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Lake Success, New York • Fairfax, Virginia
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 36
- States / cities
- Daphne, Alabama • Chandler, Arizona • Prescott Valley, Arizona + 32 more
- Conditions
- Head and Neck Cancer, Lung Cancer
- Interventions
- filgrastim, cisplatin, paclitaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 18
- States / cities
- Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more